Irinotecan

• CAT Number: I005716
• CAS Number: 97682-44-5
• Molecular Formula: C33H38N4O6
• Molecular Weight: 586.68
• Purity: ≥95%
• Target: Topoisomerase
• Solubility: DMSO: ≥ 32 mg/mL
• Storage: 2-8°C
• IC50: 15.8 μM(LoVo cells); 5.17 μM(HT-29 cells)
• IUPAC Name: [(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate
• InChI: InChI=1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1
• InChIKey: UWKQSNNFCGGAFS-XIFFEERXSA-N
• SMILES: CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7

Irinotecan（Cat No.:I005716）, also known as CPT-11, is a chemotherapeutic agent that acts by inhibiting the enzyme topoisomerase 1. By doing so, it prevents DNA from unwinding and inhibits the normal function of topoisomerase 1 in DNA replication and repair processes. This interference leads to DNA damage and ultimately cell death. Irinotecan is commonly used in the treatment of various cancers, including colorectal cancer, where it disrupts cancer cell growth and helps in managing the disease.

Reference

[1]. Roy AC, Park SR, Cunningham D, et al. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol. 2013 Feb 13 


[2]. JY Douillard, D Cunningham, AD Roth, M Navarro, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. The Lancet, 2000, 355( 9209): 1041 – 1047.


[3]. Prof Philippe Rougier, Eric Van Cutsem, Emilio Bajetta, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. The Lancet, 1998, 352 ( 9138): 1407 – 1412.


[4]. Armand JP, Ducreux M, Mahjoubi M et al. CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer. 1995 Jul-Aug;31A(7-8):1283-7.